Notizie AIOM – anno XV n. 624
FDA Approval Sought for Denosumab in Myeloma
April 5, 2017 - A supplemental biologics license application (sBLA) has been submitted to the FDA for the use of denosumab for the prevention of skeletal-related events (SREs) in patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor. ...Leggi tutto
Cancer-Related Anxiety
Experiencing anxiety after diagnosis is not unusual and often begins as a temporary worry or fear after treatment or a visit to the doctor. In severe cases, a person’s capacity to lead a normal life may be compromised and the ability to function severely impacted. ...Leggi tutto
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Given recently published results of a 750-patient adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy for treating high-risk patients is unclear. We sought to determine whether there is improved disease-free survival benefit to ...Leggi tutto
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions
The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian CancerConsensus Conference held in Tokyo, Japan, in November 2015 are reported. Three topics were reviewed and the following statements are recommended: (i) ...Leggi tutto
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum-sensitive relapsed ovarian cancer when it was used with chemotherapy and was continued as maintenance ...Leggi tutto
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
Alectinib is an anaplastic lymphoma kinase (ALK) –specific kinase inhibitor that seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALKmutations. The primary analysis of AF-001JP reported a promising overall response rate. To assess ...Leggi tutto